Ludovica F Buttó1,2, Li-Guo Jia1,2, Kristen O Arseneau1,2, Hiroshi Tamagawa3, Alex Rodriguez-Palacios1,2, Zhaodong Li1,2, Carlo De Salvo4,2, Theresa T Pizarro4,2, Giorgos Bamias5, Fabio Cominelli1,4,2. 1. Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 2. Digestive Health Research Institute, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 3. Department of Surgery, Otemae Hospital, Osaka, Japan. 4. Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 5. GI-Unit, 3rd Academic Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.
Abstract
Background: TNF-like cytokine 1A (TL1A) and its functional receptor, death-domain-receptor-3 (DR3), are multifunctional mediators of effector and regulatory immunity. We aimed to evaluate the functional role and therapeutic potential of TL1A/DR3 signaling in Crohn's disease-like ileitis. Methods: Ileitis-prone SAMP1/YitFc (SAMP) and TNFΔARE/+ mice were rendered deficient for DR3 or TL1A by microsatellite marker-assisted backcrossing. Pathological and immunological characteristics were compared between control and knockout mice, and mucosal immunophenotype was analyzed by Nanostring microarray assay. The therapeutic effect of pharmacological TL1A neutralization was also investigated. Results: DR3 deficiency was associated with restoration of a homeostatic mucosal immunostat in SAMP mice through the regulation of several pro- and anti-inflammatory genes. This led to suppression of effector immunity, amelioration of ileitis severity, and compromised ability of either unfractionated CD4+ or CD4+CD45RBhi mucosal lymphocytes to transfer ileitis to severe combined immunodeficient mice recipients. TNF-driven ileitis was also prevented in TNFΔARE/+xDR3-/- mice, in association with decreased expression of the pro-inflammatory cytokines TNF and IFN-γ. In contrast to DR3, TL1A was dispensable for the development of ileitis although it affected the kinetics of inflammation, as TNFΔARE/+xTL1A-/- demonstrated delayed onset of inflammation, whereas administration of a neutralizing, anti-TL1A antibody ameliorated early but not late TNFΔARE/+ ileitis. Conclusion: We found a prominent pro-inflammatory role of DR3 in chronic ileitis, which is only partially mediated via interaction with TL1A, raising the possibility for additional DR3 ligands. Death-domain-receptor-3 appears to be a master regulator of mucosal homeostasis and inflammation and may represent a candidate therapeutic target for chronic inflammatory conditions of the bowel.
Background: TNF-like cytokine 1A (TL1A) and its functional receptor, death-domain-receptor-3 (DR3), are multifunctional mediators of effector and regulatory immunity. We aimed to evaluate the functional role and therapeutic potential of TL1A/DR3 signaling in Crohn's disease-like ileitis. Methods: Ileitis-prone SAMP1/YitFc (SAMP) and TNFΔARE/+ mice were rendered deficient for DR3 or TL1A by microsatellite marker-assisted backcrossing. Pathological and immunological characteristics were compared between control and knockout mice, and mucosal immunophenotype was analyzed by Nanostring microarray assay. The therapeutic effect of pharmacological TL1A neutralization was also investigated. Results: DR3 deficiency was associated with restoration of a homeostatic mucosal immunostat in SAMP mice through the regulation of several pro- and anti-inflammatory genes. This led to suppression of effector immunity, amelioration of ileitis severity, and compromised ability of either unfractionated CD4+ or CD4+CD45RBhi mucosal lymphocytes to transfer ileitis to severe combined immunodeficient mice recipients. TNF-driven ileitis was also prevented in TNFΔARE/+xDR3-/- mice, in association with decreased expression of the pro-inflammatory cytokines TNF and IFN-γ. In contrast to DR3, TL1A was dispensable for the development of ileitis although it affected the kinetics of inflammation, as TNFΔARE/+xTL1A-/- demonstrated delayed onset of inflammation, whereas administration of a neutralizing, anti-TL1A antibody ameliorated early but not late TNFΔARE/+ ileitis. Conclusion: We found a prominent pro-inflammatory role of DR3 in chronic ileitis, which is only partially mediated via interaction with TL1A, raising the possibility for additional DR3 ligands. Death-domain-receptor-3 appears to be a master regulator of mucosal homeostasis and inflammation and may represent a candidate therapeutic target for chronic inflammatory conditions of the bowel.
Authors: Jesús Rivera-Nieves; Giorgos Bamias; Alda Vidrich; Marco Marini; Theresa T Pizarro; Marcia J McDuffie; Christopher A Moskaluk; Steven M Cohn; Fabio Cominelli Journal: Gastroenterology Date: 2003-04 Impact factor: 22.682
Authors: Giorgos Bamias; Charles Martin; Marco Marini; Sharon Hoang; Margarita Mishina; William G Ross; Muhammadreza A Sachedina; Charles M Friel; James Mize; Stephen J Bickston; Theresa T Pizarro; Ping Wei; Fabio Cominelli Journal: J Immunol Date: 2003-11-01 Impact factor: 5.422
Authors: John L Prehn; Shahab Mehdizadeh; Carol J Landers; Xia Luo; Stephanie C Cha; Ping Wei; Stephan R Targan Journal: Clin Immunol Date: 2004-07 Impact factor: 3.969
Authors: F Meylan; Y-J Song; I Fuss; S Villarreal; E Kahle; I-J Malm; K Acharya; H L Ramos; L Lo; M M Mentink-Kane; T A Wynn; T-S Migone; W Strober; R M Siegel Journal: Mucosal Immunol Date: 2010-10-27 Impact factor: 7.313
Authors: Li-Guo Jia; Giorgos Bamias; Kristen O Arseneau; Linda C Burkly; Eddy C Y Wang; Dennis Gruszka; Theresa T Pizarro; Fabio Cominelli Journal: J Immunol Date: 2016-05-27 Impact factor: 5.422
Authors: Abigail Hay; Jean-Martin Lapointe; Arthur Lewis; Carol Moreno Quinn; Elena Miranda Journal: Histol Histopathol Date: 2019-06-11 Impact factor: 2.303
Authors: Ludovica F Buttó; Adam Pelletier; Shyam K More; Nan Zhao; Abdullah Osme; Christopher L Hager; Mahmoud A Ghannoum; Rafick-Pierre Sekaly; Fabio Cominelli; Maneesh Dave Journal: Stem Cell Reports Date: 2020-07-16 Impact factor: 7.765